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most important cost drivers in COPD. The purpose of this analy-
sis was to assess the cost-effectiveness of tiotropium, a once daily
inhaled anticholinergic. METHODS: A cost-effectiveness analy-
sis has been performed, deﬁning effectiveness as each exacerba-
tion avoided. Effectiveness data of tiotropium and comparator
have been obtained from a one-year clinical trial comparing
tiotropium plus standard treatment (short-acting beta-
adrenergic and/or inhaled/oral corticoids) with placebo plus
standard treatment (deﬁned as above), which showed that the
group receiving tiotropium had less exacerbations per year (1.57
vs. 2.41; p < 0.01)1 Health care resources utilization has been
taken from the same clinical trial, a systematic review of the lit-
erature, and a local expert panel. The analysis has only included
direct medical costs from the perspective of the Spanish National
Health System. Drug costs were taken from an ofﬁcial source
and other costs from a Spanish health care cost database, both
dated 2005. The time horizon selected was one year, the follow-
up period of the aforementioned clinical trial. RESULTS: Total
costs per patient in the tiotropium group was €1388 and in the
placebo group €1119. Hospitalisation costs accounted for 44%
and 84% in the tiotropium and placebo group, respectively. The
incremental cost-effectiveness ratio was €320 to prevent one
exacerbation in a COPD patient when using tiotropium instead
of placebo. CONCLUSIONS: The use of tiotropium in addition
to the standard treatment as deﬁned in the clinical trial from
which effectiveness data were derived is a cost-effective measure
in the management of patients with COPD in Spain. 1MISTRAL
study—Eur Resp J 2004;24(Suppl. 48):S513.
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OBJECTIVE: To estimate the cost-effectiveness of Tiotropium
compared with Salmeterol in Greece from the perspective of
National Health System. METHODS: A Markov model was
structured around disease states and exacerbations based on
patient-level data derived from clinical trials comparing
tiotropium (18 ìg qd) with Salmeterol (50 ìg bid) [1]. At the start
of the model simulation, 20% of the patients were assumed to
have moderate COPD, 50% severe and 30% very severe COPD
according to the international GOLD classiﬁcation. During each
Markov cycle patients had a certain probability to experience a
severe or non-severe exacerbation. An exacerbation was clini-
cally deﬁned as a complex of respiratory symptoms. Costs of
exacerbations were divided into hospitalization and other costs.
Total costs comprise of the costs for exacerbations and mainte-
nance therapy. All costs are expressed in 2004 Euro. The time
horizon of the analysis was one year. RESULTS: The mean
number of exacerbations per patient in one year was 0.92 in the
tiotropium arm, and 1.1 in the salmeterol arm, resulting in 0.18
exacerbations avoided per patient and year when using
tiotropium instead of salmeterol. The total costs per patient in
one year were €1.324 in the tiotropium arm, and €1.239 in the
salmeterol arm, resulting in a cost difference of €85. The higher
acquisition costs for tiotropium were almost offset by savings in
hospitalisation costs. The incremental cost per exacerbation
avoided was €472. CONCLUSION: Tiotropium appears to be a
cost-effective treatment for the Greek health care system with
acceptable costs per exacerbation avoided. [1] Oostenbrink J,
Rutten-van Molken M, Monz B, FitzGerald J. Probabilistic
Markov model to assess the cost-effectiveness of bronchodilator
therapy in COPD patients in different countries. Value Health
2005;8:32–46.
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OBJECTIVES: To evaluate short term cost-effectiveness of fen-
spiride therapy in patients with chronic bronchitis exacerbations
in Poland. METHODS: A cost-effectiveness analysis was per-
formed based on the results of a randomized controlled clinical
trial comparing fenspiride and placebo in the concomitant treat-
ment of chronic bronchitis. The study population (n = 183 age
57 ± 9) was treated with fenspiride 80mg or placebo twice daily
for 6 months. The number and duration of acute exacerbations
of chronic bronchitis (AECB) deﬁned according to the American
Thoracic Society were the main efﬁcacy criteria. Cost analysis
was performed from the societal perspective. Costs of medical
consultations and diagnostic tests were based on the Polish
National Health Fund rates index. Indirect costs were calculated
using human capital approach. RESULTS: Number and duration
(days) of AECB over 6 months were lower in the fenspiride group
compared to the placebo group, on average 0.56 vs. 1.0 and 3.21
vs. 6.54, respectively. The number needed to treat (NNT) to
avoid an AECB episode was 2.27 over 6 months. In the popu-
lation of patients with exacerbations, 32% of fenspiride group
and 60.5% of placebo group experienced more than one AECB
episode. In this population the NNT to avoid an AECB episode
was 1.85 over 6 months. Taking only direct costs into consider-
ation, the incremental cost-effectiveness ratio of fenspiride was
€19.61 for one AECB episode. Indirect costs equaled €43.79 per
patient per one day of AECB. In the fenspiride group indirect
costs constituted 61% and in the placebo group 82% of the total
costs. Including direct and indirect costs, fenspiride concomitant
treatment is a cost-saving alternative. CONCLUSION: In
Poland, concomitant treatment of chronic bronchitis with fen-
spiride is a cost-effective alternative in patients who experienced
AECB.
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OBJECTIVES: To compare early polipectomy based strategy
with initial treatment with ﬂuticasone propionate nasal drops
(FPND) for the treatment of bilateral nasal polyposis in adults
in Poland. METHODS: A decision analytic model was developed
to reﬂect current clinical practice in management of bilateral
nasal polyposis in Poland. Early polypectomy, preceded by com-
puted tomography and followed by FPND for four months was
compared with initial treatment with FPND. In case of treatment
failure of the drug based strategy, patients were treated with sys-
temic corticosteroids and thereafter polypectomy. Data on treat-
ment methods efﬁcacy were derived from literature review. Cost
analysis was performed from payer perspective. Sensitivity analy-
sis focused on surgical treatment costs and FPND efﬁcacy.
